{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:34:43Z","timestamp":1792636483422,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T00:00:00Z","timestamp":1260403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\n\t\t\t\t\t<\/jats:bold> Allergen\u2010specific immunotherapy, subcutaneous immunotherapy (SCIT) or oral, has been used for almost a century to redirect inappropriate immune responses in atopic patients. A new mode of administration through the intact skin [epicutaneous immunotherapy (EPIT)], using an original epicutaneous delivery system, may represent an alternative to these classical methods.<\/jats:p><jats:p><jats:bold>Objective\n\t\t\t\t\t<\/jats:bold> Proof of concept of efficacy of EPIT on intact skin in mice sensitized to aeroallergens or food allergens.<\/jats:p><jats:p><jats:bold>Methods\n\t\t\t\t\t<\/jats:bold> Mice were sensitized to pollen (<jats:italic>n<\/jats:italic>=18), house dust mite (HDM, <jats:italic>n<\/jats:italic>=24), ovalbumin (OVA, <jats:italic>n<\/jats:italic>=18) or peanut (<jats:italic>n<\/jats:italic>=18), and allocated to four groups: EPIT, SCIT, not treated (NT) and control. Specific Ig (sIg)E, sIgG1 and sIgG2a were monitored. After 8 weeks of treatment, plethysmography was performed after aerosol provocation with appropriate allergens.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> At the highest doses of methacholine, pause enhancement (Penh) values were significantly decreased in the EPIT group vs. the sensitized NT groups (7.5 vs. 12.3 \u2013 pollen, 7.6 vs. 8.9 \u2013 HDM, 11.5 vs. 14.5 \u2013 OVA, 7.6 vs. 12.8 \u2013 peanut, respectively) (<jats:italic>P<\/jats:italic>&lt;0.05). With all the allergens tested, Penh values were similar in SCIT, EPIT and control. IgG2a for pollen, HDM, OVA and peanuts were significantly increased in the EPIT group vs. NT: 0.97 vs. 0.42\u2003\u03bcg\/mL, 2.5 vs. 0.46\u2003\u03bcg\/mL, 0.39 vs. 0.05\u2003\u03bcg\/mL and 15.0 vs. 5.5\u2003\u03bcg\/mL, respectively (<jats:italic>P<\/jats:italic>&lt;0.05). There were no significant differences between EPIT and SCIT groups. The IgE\/IgG2a ratio decreased significantly in the EPIT group for the four allergens from 70 to 58 (pollen), 175 to 26 (HDM), 5433 to 120 (OVA) and 49 to 6 (peanut), respectively (<jats:italic>P<\/jats:italic>&lt;0.05).<\/jats:p><jats:p><jats:bold>Conclusion\n\t\t\t\t\t<\/jats:bold> In mice sensitized to the four allergens tested, EPIT was as efficacious as SCIT, considered as the reference immunotherapy. These first results have to be confirmed by clinical studies.<\/jats:p><jats:p> <jats:italic>Cite this as<\/jats:italic>: L. Mondoulet, V. Dioszeghy, M. Ligouis, V. Dhelft, C. Dupont and P.\u2010H. Benhamou, <jats:italic>Clinical &amp; Experimental Allergy<\/jats:italic>, 2010 (40) 659\u2013667.<\/jats:p>","DOI":"10.1111\/j.1365-2222.2009.03430.x","type":"journal-article","created":{"date-parts":[[2010,8,2]],"date-time":"2010-08-02T23:32:43Z","timestamp":1280791963000},"page":"659-667","source":"Crossref","is-referenced-by-count":153,"title":["Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy"],"prefix":"10.1111","volume":"40","author":[{"given":"L.","family":"Mondoulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Dioszeghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ligouis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Dhelft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.\u2010H.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)78276-6"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)40417-X"},{"key":"e_1_2_6_4_2","first-page":"20","article-title":"World Health Organization position paper. Allergen immunotherapy","volume":"53","author":"Bousquet J","year":"1998","journal-title":"therapeutis=cal vaccines for allergic diseases"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1258\/0007142001903517"},{"key":"e_1_2_6_6_2","first-page":"497","article-title":"Monitoring allergen immunotherapy of pollen\u2010allergic patients","volume":"29","author":"Gehlhar K","year":"1999","journal-title":"the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome"},{"key":"e_1_2_6_7_2","first-page":"301","article-title":"Three years of specific immunotherapy with house\u2010dust\u2010mite extracts in patients with rhinitis and asthma","volume":"56","author":"Pichler CE","year":"2001","journal-title":"significant improvement of allergen-specific parameters and of non-specific bronchial hyperreactivity"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121317"},{"key":"e_1_2_6_9_2","first-page":"59","article-title":"Immunologic responses to subcutaneous allergen immunotherapy","volume":"21","author":"Till SJ","year":"2008","journal-title":"Clin Allergy Immunol"},{"key":"e_1_2_6_10_2","first-page":"5","article-title":"Sublingual immunotherapy","volume":"61","author":"Bousquet J.","year":"2006","journal-title":"validated"},{"key":"e_1_2_6_11_2","first-page":"144","article-title":"Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation","volume":"111","author":"Wiedermann U","year":"1998","journal-title":"cholera toxin induces a Th1-like immune response to Bet v1, the major birch pollen allergen"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.09.033"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.08.033"},{"key":"e_1_2_6_14_2","first-page":"1394","article-title":"Allergenic group specificity & therapeutic consequences in asthma; specific desensitization method by epicutaneous route","volume":"33","author":"Pautrizel R","year":"1957","journal-title":"Sem Hop"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.3.9606031"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2006.02624.x"},{"key":"e_1_2_6_17_2","first-page":"622","article-title":"Allergen immunotherapy inhibits airway eosinophilia and hyperresponsiveness associated with decreased IL\u20104 production by lymphocytes in a murine model of allergic asthma","volume":"19","author":"Van Oosterhout AJML","year":"1998","journal-title":"Cell Mol Biol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02660.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03260.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI2686"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1647"},{"key":"e_1_2_6_22_2","unstructured":"MondouletL DioszeghyV LigouisM BerchetA DupontC BenhamouPH.Dose effect of epicutaneous immunotherapy (EPIT) for peanut allergy in murine model. 2009 EAACI June 2009 Warsaw."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000109290"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","unstructured":"DioszeghyV MondouletL DhelftV DupontC BenhamouPH.In epicutaneous immunotherapy application of allergen on intact skin results in rapid uptake by the dendritic cells in sensitized mice. EAACI Congress 2009.","DOI":"10.1016\/j.clim.2009.03.241"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","unstructured":"DioszeghyV MondouletL DhelftV DupontC BenhamouPH.Epicutaneous immunotherapy application of allergen on intact skin result on rapid uptake by the dendritic cells in sensitized mice. EEACI Congress 2009.","DOI":"10.1016\/j.clim.2009.03.241"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02260.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.01989.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02401.x"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.2009.03430.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.2009.03430.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:00:16Z","timestamp":1697454016000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.2009.03430.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,11]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1365-2222.2009.03430.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.2009.03430.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,11]]}}}